Apheris
Apheris provides secure, federated machine learning platforms that enable life sciences organizations to collaboratively train AI models on sensitive, proprietary data without moving it from their local environments.
Classification
Profile
Funding
Funding details not yet available.
Fundraising & market
Enables secure, local AI inference and collaborative model training on sensitive data without data leaving the customer's environment.
Large global life sciences organizations requiring collaboration on sensitive, proprietary data across borders and teams.
Licensing AI models and secure platform access via enterprise SaaS subscriptions.
Direct sales to enterprise clients via website and targeted outreach.
life sciences data networks, pharma companies for data contribution
R&D for AI models, secure infrastructure hosting, and enterprise sales efforts.
Federated learning platform, secure local inference technology, and expertise in distributed machine learning for life sciences.
Developing secure local applications, enabling collaborative model training, and facilitating in-house benchmarking for drug discovery.
Sales-led with dedicated support for enterprise compliance and integration needs.
Competes in secure AI for life sciences by offering local inference to keep data in-house, differentiating from cloud-based federated learning.
Inability to collaborate on sensitive data due to privacy regulations and the risk of exposing proprietary information during model training.
- Tiered pricing for SMBs - Introduce a low-cost entry tier (e.g., “Starter”) to capture early-stage biotech startups and academic labs, ex
Value ↔ Customer Segments - The privacy-preserving promise directly solves the data-silo pain point of pharma R&D, making the value propos · Channels ↔ Revenue - Direct sales and partner-embedded channels feed the subscription model; professional services and marketplace royalties · Key Resources ↔ Key Activities - The federated platform (resourc
- Domain-specific depth: Apheris’ focus on structural biology and ADMET, backed by a roster of top-tier pharma partners, gives it a clear a
No investors recorded yet.